Therapeutic Targets

Glioblastoma

 

Glioblastoma is a highly malignant brain tumor for which current therapeutic options provide only a modest improvement in outlook. New treatments of glioblastoma are urgently needed. RAGE may play a role in the growth and invasiveness of glioblastoma and its resistance to current treatments.

 

 

Brain Metastasis

 

The spread (metastasis) of cancer to the brain is a common occurrence in patients with lung cancer and breast cancer, as well as many other cancers. Brain metastases can be resistant to the effect of radiation therapy and pre-clinical data suggests that RAGE inhibition may overcome this resistance.

 

 

Cancer-Related Cognitive Decline

 

Cancer-related cognitive decline, often referred to as “chemobrain” commonly occurs in people receiving high doses of chemotherapy. Pre-clinical data suggests that azeliragon may lessen or prevent cancer-related cognitive decline when given in conjunction with chemotherapy.

 

 

Pancreatic Cancer

 

Pancreatic cancer, unless controlled at its earliest stages, tends to spread to local tissues and to distant organs. Although surgery can be curative if pancreatic cancer is diagnosed at its very earliest stages, once the cancer has spread to distant organs, the current treatment has some, although limited, efficacy. New treatments are clearly needed. RAGE has been implicated in the growth and spread of pancreatic cancer and its resistance to chemotherapy.

microscope and Doctor holding tablet